Internal award provides funding to cross-disciplinary project
Chronic alcohol exposure — whether from fetal exposure during development or binge drinking during adolescence and adulthood — impairs brain development and function.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Research suggests that the brain’s resident immune cells (called microglia) play an important role in this harmful process, as they regulate neuronal networks during critical periods of brain development and protect the brain against injury and disease. Additionally, research shows that chronic alcohol exposure damages the barrier cells that line the organs of the digestive system.
As understanding of the microbiome and its importance to overall health has advanced over recent years, researchers from Cleveland Clinic Lerner Research Institute’s Department of Inflammation and Immunity and the Department of Neurosciences wonder if gut-brain interactions may influence microglia’s role in alcohol-related neurotoxicity.
Laura Nagy, PhD, who studies alcohol’s effects on the intestines and innate immune signaling, and Dimitrios Davalos, PhD, who has expertise in neuroinflammation and neurodegeneration, lead the cross-department collaboration.
The team will investigate using preclinical models and imaging technologies developed in Dr. Davalos’ lab how increasing alcohol exposure affects the interactions between microglia and neurons, and leads to neuronal dysfunction.
They will go on to investigate whether preventing alcohol-induced loss of gut integrity using a therapeutic agent previously developed in Dr. Nagy’s lab (hyaluronic acid, also called HA35) can curb microglial activation and subsequent neuroinflammation. They will validate their findings with brain tissue collected from patients with a history of alcohol-related pathologies and stored at Cleveland Clinic.
If the team finds that HA35 does in fact protect the gut and prevents alcohol-related neuroinflammation, there is great hope for rapid translation into clinical trials as HA35 is currently undergoing safety testing in healthy adults.
This project is one of two projects funded by a new internally funded award, called the Co-Laboratories Award. It encourages new, “start-up” collaborations that bring together researchers from different laboratories to investigate and attack disease from many angles, drawing on the unique expertise and innovations that each laboratory has to offer.
The Co-Laboratories Award is important not just because it forges new and otherwise unlikely collaborations between people across Lerner Research Institute, but also because it makes early stage research possible. This seed funding will provide the data these researchers need to secure larger funds from external sources, like foundations and the National Institutes of Health.
Investigators are developing a deep learning model to predict health outcomes in ICUs.
Cleveland Clinic and Johns Hopkins collaboration could help meet need for new therapies
Cleveland Clinic researchers’ finding paves the way for new antiviral approaches
Multicenter collaboration aims to facilitate tracking of neurological activity deep within tissue
Findings illuminate MCEMP1 protein’s role in severe inflammation
Anti-viral immunity identified a novel mechanism in necroptosis
Cleveland Clinic’s new Global Director of Vaccine Development outlines plans, priorities
Collaborative involving Cleveland Clinic investigators focuses on antiviral drug development